RecruitingPhase 2NCT07325539

LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC

Low-dose Radiotherapy (LDRT) Combined With Toripalimab and GP Chemotherapy for Recurrent/Metastatic Nasopharyngeal Carcinoma (LIGHT): A Multicentre, Open-Label, Single-Arm Phase II Clinical Study

Sponsor

Sun Yat-sen University

Enrollment

55 participants

Start Date

Jan 12, 2026

Study Type

INTERVENTIONAL

Conditions

Nasopharangeal Cancer Nasopharyngeal Cancinoma (NPC)

Summary

This study aims to evaluate the efficacy and safety of LDRT combined with toripalimab and GP chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma through a prospective, open-label, single-arm Phase II clinical trial.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Cisplatin, a drug called Gemcitabine(GEM), and others for people with nasopharangeal cancer and nasopharyngeal cancinoma (npc). The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGGemcitabine(GEM)

Gemcitabine 1000mg/m2, d1 \& 8 of every cycle, every 3 weeks for 4-6 cycles

DRUGCisplatin

Cisplatin 80mg/m2, d1 of every cycle, every 3 weeks for 4-6 cycles

DRUGToripalimab

Toripalimab 240 mg, d1of every cycle, every 3 weeks for 4-6 cycles. Toripalimab maintenance, 240 mg, d1of every cycle, every 3 weeks until disease progression or unacceptable toxicity.

RADIATIONLDRT

Irradiation of the primary lesion and regional metastatic lymph nodes, 0.5 Gy per fraction for 4 fractions, d0-3, every 3 weeks for 4-6 cycles

Locations(2)

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China

Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Shenzhen, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07325539

Related Trials

DESTINY-PANTUMOUR04

NCT0712400018 locations

Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma

NCT075281834 locations

Efficacy and Safety of Becotatug Vedotin (MRG003) Combined With Anti-PD1 as Maintenance Therapy for Recurrent and Metastatic Nasopharyngeal Carcinoma

NCT077052431 location

LDRT and Chemoimmunotherapy in NPC With Liver Metastasis

NCT067880028 locations

Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors

NCT076254231 location